A Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FMS-like tyrosine kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Trial Identifier: 2215-CL-1101
Sponsor: Astellas Pharma Global Development, Inc.
Start Date: June 2019
Primary Completion Date: May 2021
Study Completion Date: June 2021
Condition: Leukemia

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, CA Los Angeles, CA, United States of America, 90095
United States of America, IL Chicago, IL, United States of America, 60611
United States of America, IL Chicago, IL, United States of America, 60037
United States of America, KY Lexington, KY, United States of America, 40536
United States of America, NY Buffalo, NY, United States of America, 14263
United States of America, NY New York, NY, United States of America, 10065
United States of America, NY New York, NY, United States of America, 10032
United States of America, OH Columbus, OH, United States of America, 43210
United States of America, SC Charleston, SC, United States of America, 29425
United States of America, TN Nashville, TN, United States of America, 37232
United States of America, TX Dallas, TX, United States of America, 75390
United States of America, TX Houston, TX, United States of America, 77030
United States of America, WI Milwaukee, WI, United States of America, 53226